Latest Breaking News On - Clin gastroenterol hepatol - Page 1 : comparemela.com

Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement

Ipsen Pharma: Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver

Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a

PSC Partners Announces the First Patient Enrolled Into the WIND-PSC Study, a Global Prospective Cohort to Support the Development of New Treatments for Primary Sclerosing Cholangitis

PSC Partners and PSC Partners Canada, both patient-led non-profit organizations supporting education and research in primary sclerosing cholangitis (PSC), announced today the enrollment of the first patient into the WIND-PSC study. PSC is a rare.

Blood-Based Test Offers Effective Screening Option for Colorectal Cancer

Data from PREEMPT CRC reveal the blood-based screening test demonstrated a 79.2% sensitivity for detecting colorectal cancer.